THERAPEUTIC ADVANCES - PROTEASE INHIBITORS FOR THE TREATMENT OF HIV-1INFECTION

Background: Anti-retroviral treatment of human immunodeficiency virus (HIV) infection is undergoing great changes, brought about by a better understanding of the disease pathology. One of the most recent advanc es has been the introduction of the protease inhibitors, reversible in hibitors of HIV aspartic protease. Published data on the clinical effi cacy of these drugs are limited, but preliminary results suggest that, in combination with one or more nucleoside analogues, they represent an important advance in the treatment of patients with advanced HIV in fection. The adverse effects and potential for drug interactions, toge ther with the additional cost associated with prescribing these drugs, mean that careful selection and supervision of these patients is impe rative. Aim: To present an up-to-date review of the three most recentl y introduced protease inhibitors. Methods: Based on a review of the li terature, abstracts from relevant meetings and information from the ph armaceutical companies. Content: A review including background data on HIV infection and the treatment options. Detailed information on rito navir, saquinavir and indinavir. Conclusions: These new drugs are usef ul additions to the therapeutic current aims for the treatment of HIV infection. They need to be used under close supervision by specialists .